CN107951861A - 一种脂质纳米粒膜材料组合物 - Google Patents
一种脂质纳米粒膜材料组合物 Download PDFInfo
- Publication number
- CN107951861A CN107951861A CN201610902492.2A CN201610902492A CN107951861A CN 107951861 A CN107951861 A CN 107951861A CN 201610902492 A CN201610902492 A CN 201610902492A CN 107951861 A CN107951861 A CN 107951861A
- Authority
- CN
- China
- Prior art keywords
- membrane material
- feed composition
- material feed
- nano particle
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000012528 membrane Substances 0.000 title claims abstract description 60
- 239000000463 material Substances 0.000 title claims abstract description 57
- 150000002632 lipids Chemical class 0.000 title claims abstract description 47
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 46
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 92
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 46
- 229920001223 polyethylene glycol Chemical class 0.000 claims abstract description 29
- 229920000136 polysorbate Chemical class 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Chemical class 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 11
- 150000001768 cations Chemical class 0.000 claims abstract description 7
- 230000007935 neutral effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 239000000243 solution Substances 0.000 claims description 50
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 43
- 229920000053 polysorbate 80 Polymers 0.000 claims description 43
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 42
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 23
- -1 palmitic acid phosphatidyl-ethanolamines Chemical class 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 12
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000012266 salt solution Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 4
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 4
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 229940101027 polysorbate 40 Drugs 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- HYXWVUFYXOOASK-UHFFFAOYSA-N CCCCCCCCCCCCCC(=O)OCC(COCCOC)OC(=O)CCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCC(=O)OCC(COCCOC)OC(=O)CCCCCCCCCCCCC HYXWVUFYXOOASK-UHFFFAOYSA-N 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 240000002943 Elettaria cardamomum Species 0.000 claims 1
- 235000005300 cardamomo Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 235000013372 meat Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 239000002245 particle Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 13
- 238000013112 stability test Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 2
- 235000021322 Vaccenic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 123.4 | 7.45 | 89.2% |
2 | 132.5 | 7.96 | 83.8% |
3 | 128.1 | 8.55 | 84.9% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 120.4 | 7.78 | 80.4% |
2 | 123.4 | 7.45 | 89.2% |
3 | 143.4 | 7.03 | 86.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 135.4 | 9.23 | 78.4% |
2 | 128.0 | 8.53 | 84.7% |
3 | 123.4 | 7.45 | 89.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 129.2 | 8.53 | 82.6% |
2 | 124.6 | 7.91 | 79.3% |
3 | 123.4 | 7.45 | 89.2% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 131.4 | 5.76 | 88.4% |
2 | 127.2 | 6.66 | 91.9% |
3 | 126.4 | 6.75 | 84.6% |
制剂 | 粒径(nm) | 电位(mV) | G3139包封率(%) |
1 | 124.4 | 7.12 | 82.8% |
2 | 126.0 | 8.04 | 87.1% |
3 | 131.8 | 7.71 | 89.9% |
制剂 | 粒径(nm) | 电位(mV) | 包封率(%) |
1 | 142.6 | 7.68 | 85.2% |
2 | 134.5 | 6.63 | 87.3% |
3 | 135.8 | 7.90 | 91.4% |
Claims (16)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610902492.2A CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
EP17863062.0A EP3527201B1 (en) | 2016-10-17 | 2017-10-13 | Lipid nanoparticle film material composition |
US16/342,804 US20200237678A1 (en) | 2016-10-17 | 2017-10-13 | Lipid nanoparticle membrane composition |
PCT/CN2017/106032 WO2018072644A1 (zh) | 2016-10-17 | 2017-10-13 | 一种脂质纳米粒膜材料组合物 |
JP2019541840A JP6893245B2 (ja) | 2016-10-17 | 2017-10-13 | 脂質ナノ粒子用膜材料組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610902492.2A CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107951861A true CN107951861A (zh) | 2018-04-24 |
CN107951861B CN107951861B (zh) | 2020-12-01 |
Family
ID=61953463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610902492.2A Active CN107951861B (zh) | 2016-10-17 | 2016-10-17 | 一种脂质纳米粒膜材料组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200237678A1 (zh) |
EP (1) | EP3527201B1 (zh) |
JP (1) | JP6893245B2 (zh) |
CN (1) | CN107951861B (zh) |
WO (1) | WO2018072644A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111544317A (zh) * | 2020-04-29 | 2020-08-18 | 珀莱雅化妆品股份有限公司 | 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用 |
CN112336853A (zh) * | 2020-10-21 | 2021-02-09 | 中南大学湘雅三医院 | 一种脂质体纳米疫苗、制备方法及应用 |
CN117491546A (zh) * | 2023-06-30 | 2024-02-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质含量的检测方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116138386A (zh) * | 2023-02-20 | 2023-05-23 | 中国农业大学 | 一种对香豆酸纳米脂质体的制备方法及抑菌保鲜应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538303A (zh) * | 2007-12-25 | 2009-09-23 | 沈阳药科大学 | 一种葫芦素族单体天然脂肪酸单酯的衍生物 |
CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
CN102670510A (zh) * | 2012-05-02 | 2012-09-19 | 江苏省中医药研究院 | 穿膜肽修饰的雷公藤红素纳米结构脂质载体及在制备治疗前列腺癌、肺癌、乳腺癌药的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009120247A2 (en) * | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
CN101732349B (zh) * | 2008-11-14 | 2012-05-23 | 上海医药工业研究院 | 一种蟾酥纳米长循环脂质体及其制备方法 |
US9610367B2 (en) * | 2010-08-24 | 2017-04-04 | Canon Kabushiki Kaisha | Particle and contrast agent having the particle |
BR112015022819A8 (pt) * | 2013-03-13 | 2019-11-26 | Mallinckrodt Llc | método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal |
EP3038600B1 (en) * | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
CN105873941A (zh) * | 2013-12-16 | 2016-08-17 | 默克专利有限公司 | 生存素导向的癌症疫苗治疗 |
-
2016
- 2016-10-17 CN CN201610902492.2A patent/CN107951861B/zh active Active
-
2017
- 2017-10-13 US US16/342,804 patent/US20200237678A1/en not_active Abandoned
- 2017-10-13 WO PCT/CN2017/106032 patent/WO2018072644A1/zh active Application Filing
- 2017-10-13 JP JP2019541840A patent/JP6893245B2/ja active Active
- 2017-10-13 EP EP17863062.0A patent/EP3527201B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101538303A (zh) * | 2007-12-25 | 2009-09-23 | 沈阳药科大学 | 一种葫芦素族单体天然脂肪酸单酯的衍生物 |
CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送系统的可释放融合脂质 |
CN102670510A (zh) * | 2012-05-02 | 2012-09-19 | 江苏省中医药研究院 | 穿膜肽修饰的雷公藤红素纳米结构脂质载体及在制备治疗前列腺癌、肺癌、乳腺癌药的应用 |
Non-Patent Citations (1)
Title |
---|
XINWEI CHENG等: "The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery", 《ADVANCED DRUG DELIVERY REVIEWS》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111544317A (zh) * | 2020-04-29 | 2020-08-18 | 珀莱雅化妆品股份有限公司 | 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用 |
CN112336853A (zh) * | 2020-10-21 | 2021-02-09 | 中南大学湘雅三医院 | 一种脂质体纳米疫苗、制备方法及应用 |
CN117491546A (zh) * | 2023-06-30 | 2024-02-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质含量的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2018072644A1 (zh) | 2018-04-26 |
JP6893245B2 (ja) | 2021-06-23 |
EP3527201A4 (en) | 2020-05-27 |
EP3527201A1 (en) | 2019-08-21 |
JP2019534899A (ja) | 2019-12-05 |
CN107951861B (zh) | 2020-12-01 |
EP3527201B1 (en) | 2021-08-18 |
US20200237678A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101903018B (zh) | 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法 | |
CN107951861A (zh) | 一种脂质纳米粒膜材料组合物 | |
DE69634084T2 (de) | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer | |
CN101267805A (zh) | 制造脂质体的系统和方法 | |
JP6638072B2 (ja) | アニオン性薬物含有医薬組成物及びその製造方法 | |
EP3967649A1 (en) | Lipid nanoparticle | |
CN105051205B (zh) | 鉴定生物标记物、治疗靶点或治疗试剂的高通量筛选方法 | |
CN107951862A (zh) | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 | |
KR20190127277A (ko) | mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법 | |
Boloix et al. | Engineering pH‐Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics | |
US8598138B2 (en) | Amphiphilic nucleotide cochleate compositions and methods of using the same | |
JP3910646B2 (ja) | 「細胞への遺伝子導入用組成物」 | |
WO2020262150A1 (ja) | 脂質ナノ粒子 | |
CN101854918B (zh) | 核酸复合体及核酸转运用组合物 | |
KR102259513B1 (ko) | 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법 | |
EP2365797B1 (en) | Small interfering rna delivery | |
CN102369282B (zh) | 核酸复合体及核酸转运用组合物 | |
WO2023188830A1 (ja) | 脂質ナノ粒子 | |
WO2022244844A1 (ja) | 脂質ナノ粒子 | |
JP3908776B2 (ja) | 細胞への遺伝子導入用組成物 | |
CN1829498A (zh) | 具有不对称脂质包被的脂质微粒和制备其的方法 | |
BR102017003860A2 (pt) | composição editora de genoma, processo de obtenção e uso da mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240620 Address after: No. 28, Gaoxin Road, Jiangbei new district, Nanjing, Jiangsu 210061 Patentee after: NANJING LUYE PHARMACEUTICAL Co.,Ltd. Country or region after: China Patentee after: Nanjing Jimai Biotechnology Co.,Ltd. Address before: No. 28, Gaoxin Road, high tech Development Zone, Nanjing, Jiangsu 210061 Patentee before: NANJING LUYE PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: NANJING ASEC NANO BIOMEDICINE Co.,Ltd. |
|
TR01 | Transfer of patent right |